Home › Research › Treatments
From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease
Chanchal Sharma, Avijit Mazumder. Central nervous system agents in medicinal chemistry, 2025-09-22
Topic: Disease mechanisms in lab and animal studies
Alzheimer's disease (AD) remains one of the most pressing neurodegenerative disorders worldwide, with increasing prevalence and limited disease-modifying treatments. While recent clinical advances, including monoclonal antibodies like lecanemab and donanemab (early stage), show promise in slowing cognitive decline by targeting amyloid-beta pathology, their use is associated with risks such as amyloid-related imaging abnormalities (ARIA). Alongside these developments, preclinical innovations continue to explore novel mechanisms, including antisense oligonucleotides, TREM2 agonists, siRNA, mRNA-LNP platforms, and CRISPR-based gene editing. These approaches target tau aggregation, neuroinflammation, and genetic risk modifiers like APOE4. This review bridges the gap between preclinical research and clinical application by highlighting the mechanisms, therapeutic potential, and translational challenges of both established and emerging therapies. Emphasis is placed on biomarker-guided trials, model systems (e.g., iPSC organoids), and future directions to improve efficacy, safety, and global accessibility of AD therapeutics.
Key findings
- While recent clinical advances, including monoclonal antibodies like lecanemab and donanemab (early stage), show promise in slowing cognitive decline by targeting amyloid-beta pathology, their use is associated with risks such as amyloid-related imaging abnormalities (ARIA).
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 24 of the 56 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Central nervous system agents in medicinal chemistry) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40993929) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 24 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 24 of the 56 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Sharma, C., & Mazumder, A. (2025). From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease. Central nervous system agents in medicinal chemistry. https://doi.org/10.2174/0118715249388723250910140541
Vancouver
Sharma C, Mazumder A. From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease. Central nervous system agents in medicinal chemistry. 2025. doi:10.2174/0118715249388723250910140541. PMID: 40993929.
BibTeX
@article{sharma2025-40993929,
author = {Sharma, Chanchal and Mazumder, Avijit},
title = {{From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease}},
journal = {Central nervous system agents in medicinal chemistry},
year = {2025},
doi = {10.2174/0118715249388723250910140541},
pmid = {40993929},
url = {https://doi.org/10.2174/0118715249388723250910140541}
}
Related studies in Treatments
Also tagged “aducanumab”
332 studies in the library carry the topic tag “aducanumab”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.